Suppr超能文献

雌激素对大鼠子宫和肝脏中抗雌激素特异性结合位点的刺激作用。

Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver.

作者信息

Winneker R C, Clark J H

出版信息

Endocrinology. 1983 Jun;112(6):1910-5. doi: 10.1210/endo-112-6-1910.

Abstract

Tamoxifen and other antiestrogens bind to the estrogen receptor and to a specific antiestrogen binding site (AEBS). We have confirmed the existence of an AEBS by saturation and competitive binding analyses with [3H]tamoxifen as the radiolabeled ligand. The quantities of AEBS (pmol/g tissue) present in a low speed cytosol (25,000 X g X 30 min) of the liver and uterus vary with species and physiological state: liver, mature female rat, 82.7 +/- 6.7; ovariectomized mature rat, 46.1 +/- 2.9; immature female rat, 40.0 +/- 1.8; mature male rat, 57.3 +/- 2.7; and mature female mouse, 63.0 +/- 5.0; uterus, mature rat, 17.9 +/- 1.7; ovariectomized mature rat, 13.3 +/- 0.5; immature rat, 8.2 +/- 0.8; and mature mouse, 49.0 +/- 2.1. The dissociation constants did not differ significantly in any of the cases and were 1.5 and 2.5 nM for the liver and uterus, respectively. Developmental studies demonstrated that the liver AEBS gradually increases in both sexes from 21.0 pmol/g at birth to their respective adult levels with the only divergence occurring approximately at the time of puberty. The AEBS concentration also varied with the stage of the estrous cycle [highest at estrus (20.6 +/- 1.8) and metestrus (91.7 +/- 5.9) for the uterus and liver, respectively, and lowest at diestrus (uterus, 15.9 +/- 0.2; liver, 60.2 +/- 4.1)]. Furthermore, estradiol treatment of ovariectomized rats significantly increased both liver and uterine AEBS levels, whereas tamoxifen increased uterine AEBS concentration although having no significant effect on the level of these sites in liver. These results demonstrate the presence of a cytosolic AEBS in the liver and uterus which is distinct from the estrogen receptor and appears to be under estrogenic regulation.

摘要

他莫昔芬及其他抗雌激素药物可与雌激素受体及特定抗雌激素结合位点(AEBS)结合。我们已通过以[³H]他莫昔芬作为放射性标记配体的饱和及竞争性结合分析证实了AEBS的存在。肝脏和子宫低速胞质溶胶(25,000×g×30分钟)中存在的AEBS量(pmol/g组织)因物种和生理状态而异:肝脏,成年雌性大鼠,82.7±6.7;去卵巢成年大鼠,46.1±2.9;未成年雌性大鼠,40.0±1.8;成年雄性大鼠,57.3±2.7;成年雌性小鼠,63.0±5.0;子宫,成年大鼠,17.9±1.7;去卵巢成年大鼠,13.3±0.5;未成年大鼠,8.2±0.8;成年小鼠,49.0±2.1。在任何情况下,解离常数均无显著差异,肝脏和子宫的解离常数分别为1.5 nM和2.5 nM。发育研究表明,两性肝脏中的AEBS从出生时的21.0 pmol/g逐渐增加至各自的成年水平,唯一的差异大约出现在青春期。AEBS浓度也随发情周期阶段而变化[子宫和肝脏分别在发情期(20.6±1.8)和动情后期(91.7±5.9)最高,在间情期最低(子宫,15.9±0.2;肝脏,60.2±4.1)]。此外,对去卵巢大鼠进行雌二醇处理可显著提高肝脏和子宫的AEBS水平,而他莫昔芬可增加子宫AEBS浓度,尽管对肝脏中这些位点的水平无显著影响。这些结果表明,肝脏和子宫中存在一种胞质溶胶AEBS,它与雌激素受体不同,且似乎受雌激素调节。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验